Characterization of Crohn’s Disease at a Cellular Level


About this study

The purpose of this study is to define and genotype the immunomodulatory properties of mesenchymal stem cells (MSCs) from Crohn’s disease subjects as compared to healthy/control subjects (diverticulitis, ulcerative colitis or subjects with perianal disease including hemorrhoids, cryptoglandular fistula, anal fissure, anal skin tags) or colon and rectal subjects.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Adult subjects undergoing surgery for one of these conditions: Crohn’s, colon and rectal surgery, diverticulitis, ulcerative colitis, perineal disease, etc.

Exclusion Criteria: 

  1. Patients under the age of 18
  2. Known HIV positive
  3. Known hepatitis B/C
  4. Self-reported pregnant or lactating


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Amy Lightner, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer